HeartBeam announced that its management team will participate in several investor and industry conferences throughout March 2026, with a focus on showcasing its FDA-cleared cardiac monitoring technology. CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, which will include a webcast presentation. The executives will also meet with institutional and retail investors during the event. Later in the month, Eno will attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where he is scheduled to join a panel discussion focused on technologies that advance healthy aging.
The company's most significant medical industry appearance will be at ACC.26, the American College of Cardiology's annual scientific conference from March 28-30. At this event, Eno, along with Founder and President Dr. Branislav Vajdic and Chief Commercial Officer Bryan Humbarger, will showcase the company's FDA-cleared HeartBeam System. A key demonstration at the cardiology conference will be a working prototype of HeartBeam's 12-lead ECG extended wear patch, which will be shown to physicians and potential industry partners. The company's core technology platform is designed to create the first cable-free device capable of collecting electrocardiogram signals in three dimensions from non-coplanar directions and synthesizing them into a standard 12-lead ECG.
This portable technology is intended to allow physicians to identify cardiac health trends and acute conditions outside of traditional medical facilities, potentially redefining cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology. The latest news and updates relating to the company are available in its newsroom at https://ibn.fm/BEAT. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN at http://IBN.fm/Disclaimer.
The implications of HeartBeam's conference participation are significant for both the medical technology industry and cardiac care patients. By demonstrating its working prototype at the American College of Cardiology's premier conference, the company positions itself at the forefront of cardiac monitoring innovation. The technology's ability to generate standard 12-lead ECGs from a portable, cable-free device represents a potential paradigm shift in how cardiac conditions are monitored and diagnosed. Traditional 12-lead ECGs require patients to be in clinical settings with multiple wired electrodes attached to their bodies, limiting continuous monitoring capabilities and early detection of cardiac events.
HeartBeam's approach could enable extended cardiac monitoring in real-world environments, potentially identifying arrhythmias and other cardiac issues that might be missed during brief clinical visits. This matters because cardiovascular disease remains a leading cause of death globally, and improved monitoring technologies could lead to earlier interventions and better patient outcomes. The company's FDA clearances for both its 3D ECG technology and 12-lead ECG synthesis software provide regulatory validation of its approach, while its patent portfolio suggests substantial intellectual property protection. The conference presentations provide opportunities for medical adoption, partnership development, and investor engagement that could accelerate the technology's path to market and clinical implementation.
